{"version":"1.0","provider_name":"Avalere Health Advisory","provider_url":"https:\/\/advisory.avalerehealth.com","title":"Final CMS Alzheimer\u2019s Coverage Memo Will Impact Access Beyond Medicare | Avalere Health Advisory","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"viic73OBw8\"><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/final-cms-alzheimers-coverage-memo-will-impact-access-beyond-medicare\">Final CMS Alzheimer\u2019s Coverage Memo Will Impact Access Beyond Medicare<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/advisory.avalerehealth.com\/insights\/final-cms-alzheimers-coverage-memo-will-impact-access-beyond-medicare\/embed#?secret=viic73OBw8\" width=\"600\" height=\"338\" title=\"&#8220;Final CMS Alzheimer\u2019s Coverage Memo Will Impact Access Beyond Medicare&#8221; &#8212; Avalere Health Advisory\" data-secret=\"viic73OBw8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","thumbnail_url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2022\/04\/3180-1-Megan_West-400x600-1.jpg","thumbnail_width":600,"thumbnail_height":400,"description":"In the context of the Centers for Medicare and Medicaid Services&#8217; (CMS) final coverage decision on amyloid beta-targeting monoclonal antibodies for Alzheimer\u2019s Disease, stakeholders are seeking to understand how the CMS coverage policy will impact future access not only for Alzheimer\u2019s Disease therapies but also for other novel agents in therapeutic areas of unmet need,&hellip;"}